In this study, SBT/carcinoma pairs showed concordant profiles in 56% of KRAS-mutated tumor cases, 31% of wild-type tumor cases, and only 13% of BRAF-mutated tumor cases [3]. This evidence concerns the gene KRAS and carcinoma.